Evidence map›Paper›PMID 33789283›Full record

ArticleNeuro-degenerative diseases2020

Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale.

Alexander Pantelyat, Lenora Higginbotham, Liana Rosenthal, Diane Lanham, Vanessa Nesspor, Mina AlSalihi, Jee Bang, Jiangxia Wang, Marilyn Albert

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-degenerative diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Alexander PantelyatDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Lenora HigginbothamDepartment of Neurology, Emory University School of Medicine, Atlanta, Georgia, USA.
Liana RosenthalDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Diane LanhamDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Vanessa NessporDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Mina AlSalihiKansas City University College of Osteopathic Medicine, Kansas City, Missouri, USA.
Jee BangDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Jiangxia WangDepartment of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Marilyn AlbertDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Johns Hopkins University · USEmory University · USKansas City University · US

Funding

Multi-modal magnetic resonance imaging in progressive supranuclear palsy (PSP)K23AG059891 · NIA · JOHNS HOPKINS UNIVERSITY · PI PANTELYAT, ALEXANDER Y. · 2018 to 2022
$968k
NIA NIH HHS K23 AG059891NIA NIH HHS L30 AG064696
6 · The paper itself

Abstract

introductionThere is growing interest in using patient-reported outcomes as end points in clinical trials, such as the progressive supranuclear palsy quality of life (PSP-QoL) scale. However, this tool has not been widely validated and its correlation with validated motor scales has not been explored. To evaluate the potential utility of using PSP-QoL as an outcome, it is important to examine its relationship with a standard scale used to evaluate neurologic parameters, such as the PSP Rating Scale.

methodsPSP-QoL and PSP Rating Scale scores were gathered from 60 clinically diagnosed PSP patients, including patients with Richardson syndrome PSP (PSP-RS, n = 43) and those with non-RS PSP variants (n = 17). Linear regression analysis adjusted for age, sex, and disease duration was used to evaluate the cross-sectional relationship between the total and subscale scores of the 2 instruments.

resultsAmong 60 PSP patients, there was a significant correlation between total PSP-QoL and PSP Rating Scale scores. The physical and mentation subscales of each instrument also demonstrated significant correlations. Comparisons among PSP subtypes indicated that worsening PSP-QoL Total and Physical subscale scores correlated with worsening PSP Rating Scale gait subscale scores more strongly for the non-RS PSP variants than for PSP-RS. DISCUSSION: There is a significant association between the total scores and many of the subscale scores of the PSP-QoL and the PSP Rating Scale. Additionally, the relationship between these measures may differ for PSP-RS and non-RS variants. These findings suggest that the PSP-QoL may be useful in clinical trials as a patient-reported outcome measure. Large prospective multicenter studies utilizing the PSP-QoL are necessary to examine its relationship to disease evolution and changes in the PSP Rating Scale.

Indexed as

Quality of LifeSupranuclear Palsy, ProgressiveHumansProspective StudiesProgressive supranuclear palsyProgressive supranuclear palsy rating scaleQuality of life

Identifiers

PMID33789283
PMCPMC8119324
OpenAlexW3148784388

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.